Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | RARB | P10826 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7761726 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL762229 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL14585844 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL13763451 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL21167283 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL22207170 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL22207172 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL22207529 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL22207285 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL14583368 | 1.00 | NR5A1 (0.68) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378205-B2 | Process for the preparation of triazine intermediates and a process for the preparation of UV absorbers thereof | BASF SE (DE) | 2025-08-05 | — | — | US | disclosed |
| US-12291509-B2 | Process for the preparation of UV absorbers | BASF SE (DE) | 2025-05-06 | — | — | US | disclosed |
| EP-3626802-B1 | METHOD FOR PRODUCING LIQUID COMPOSITION | SUMITOMO CHEMICAL CO (JP) | 2024-12-25 | — | — | EP | disclosed |
| US-20240240024-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN LAYER USING THE SAME, AND COLOR FILTER | SAMSUNG SDI CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-3908576-B1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | BASF SE (DE) | 2023-03-08 | — | — | EP | disclosed |
| US-20220119357-A1 | A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220064129-A1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | BASF CHEMICALS INDIA PVT. LTD. (IN) | 2022-03-03 | — | — | US | disclosed |
| EP-3908576-A1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | BASF SE (DE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3908633-A1 | A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF | BASF SE (DE) | 2021-11-17 | — | — | EP | disclosed |
| CN-113260679-A | Process for preparing triazine intermediates and process for preparing UV absorbers thereof | 巴斯夫欧洲公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2007-10-11 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | IFNG, IRF3, MAVS | NR5A1 4113/4885LTA4H 2553/4885TP53 26/4885 |
| US-20220119357-A1 | A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF | DHPS, NISCH, UNG | NR5A1 2858/4885LTA4H 1553/4885TP53 1250/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | NR5A1 3979/4885LTA4H 2228/4885TP53 68/4885 |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | CERS2, UGCG, SGMS1 | NR5A1 3398/4885LTA4H 435/4885TP53 3281/4885 |
| US-12378205-B2 | Process for the preparation of triazine intermediates and a process for the preparation of UV absorbers thereof | DHPS, UNG, UMPS | NR5A1 2592/4885LTA4H 1407/4885TP53 1240/4885 |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | NR5A1 653/4885LTA4H 2849/4885TP53 4367/4885 |
| US-20220064129-A1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | UNG, ERCC4, UROD | NR5A1 2566/4885LTA4H 1221/4885TP53 1061/4885 |
| US-12291509-B2 | Process for the preparation of UV absorbers | UNG, UROD, ERCC4 | NR5A1 2673/4885LTA4H 1178/4885TP53 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.